Early Evidence of the Effectiveness of the Human Papillomavirus Vaccination Program Against Anogenital Warts in Manitoba, Canada

2018 ◽  
Vol 45 (4) ◽  
pp. 254-259 ◽  
Author(s):  
Karla Willows ◽  
Songul Bozat-Emre ◽  
Christiaan H. Righolt ◽  
Erich V. Kliewer ◽  
Salaheddin M. Mahmud
2016 ◽  
Vol 29 (2) ◽  
pp. 101 ◽  
Author(s):  
Ana Gameiro ◽  
João Alves ◽  
Irene Santo ◽  
Jacinta Azevedo

<p><strong>Introduction:</strong> Human papillomavirus infection is the most common sexual transmitted infection in the world, being associated with different diseases, namely anogenital warts, recurrent respiratory papillomatosis and anal, cervical, and oropharyngeal cancers. Among sexually active people, approximately 1% has anogenital warts, 90% of cases resulting from genotypes 6 and 11.<br /><strong>Material and Methods:</strong> Patients diagnosed with first episode of anogenital warts from 2008 to 2014 in Lisbon’s major venereology clinic were identified, and characterized according to sex, sexual orientation, age, warts location, and number of sexual partners. <br /><strong>Results:</strong> We observed a statistically significant decrease in first anogenital warts diagnosis among &lt; 19 year old females (r = -0.848;<br />p = 0.016) and a non-statistically significant decrease among &lt; 19 – year-old males and among 20 – 24 year old females.<br /><strong>Discussion:</strong> In October 2008, the quadrivalent vaccine (genotypes 6, 11, 16, 18) was introduced in the Portuguese national vaccination program, targeting 13-year-old females, with a catch-up for 17 year old females. In the women´s group, decrease in first anogenital warts diagnosis is probably related to human papillomavirus vaccination before onset of sexual activity.<br /><strong>Conclusion:</strong> This study reinforces the importance of national human papillomavirus vaccination program.</p>


2017 ◽  
Vol 90 (3) ◽  
pp. 592-598 ◽  
Author(s):  
Marc Steben ◽  
Najwa Ouhoummane ◽  
Caroline Rodier ◽  
Liliya Sinyavskaya ◽  
Paul Brassard

2019 ◽  
Vol 8 ◽  
pp. 100189 ◽  
Author(s):  
Sapna Kaul ◽  
Thuy Quynh N. Do ◽  
Enshuo Hsu ◽  
Kathleen M. Schmeler ◽  
Jane R. Montealegre ◽  
...  

2016 ◽  
Vol 215 (3) ◽  
pp. 318.e1-318.e9 ◽  
Author(s):  
Abbey B. Berenson ◽  
Mahbubur Rahman ◽  
Jacqueline M. Hirth ◽  
Richard E. Rupp ◽  
Kwabena O. Sarpong

Sexual Health ◽  
2015 ◽  
Vol 12 (6) ◽  
pp. 520 ◽  
Author(s):  
Luke B. Connelly ◽  
Ha N. D. Le

Background Human papillomavirus (HPV) vaccines and their widespread adoption have the potential to relieve a large part of the burden of cervical cancer morbidity and mortality, particularly in countries that have low screening rates or, like Japan, lack a cohesive universal screening program. An economic evaluation was conducted to assess the cost-effectiveness of introducing a bivalent HPV vaccination program in Japan from a healthcare perspective. Methods: A Markov model of the natural history of HPV infection that incorporates both vaccination and screening was developed for Japan. The modelled intervention, a bivalent HPV vaccine with a 100% lifetime vaccine efficacy and 80% vaccine coverage, given to a cohort of 12-year-old Japanese girls in conjunction with the current screening program, was compared with screening alone in terms of costs and effectiveness. A discount rate of 5% was applied to both costs and utilities where relevant. Results: Vaccination alongside screening compared with screening alone is associated with an incremental cost-effectiveness ratio (ICER) of US$20 315 per quality-adjusted-life-year gained if 80% coverage is assumed. The ICER at 5% coverage with the vaccine plus screening, compared with screening alone, is US$1158. Conclusion: The cost-effectiveness results suggest that the addition of a HPV vaccination program to Japan’s cervical cancer screening program is highly likely to prove a cost-effective way to reduce the burden of cervical cancer, precancerous lesions and HPV16/18-related diseases.


2011 ◽  
Vol 14 (7) ◽  
pp. A277-A278
Author(s):  
V. Omelyanovsky ◽  
M. Avxentyeva ◽  
I. Krysanov ◽  
O. Ivakhnenko ◽  
S. Goryaynov ◽  
...  

2019 ◽  
Vol 46 (4) ◽  
pp. 213-220 ◽  
Author(s):  
Anthony E. Yakely ◽  
Lital Avni-Singer ◽  
Carlos R. Oliveira ◽  
Linda M. Niccolai

Sign in / Sign up

Export Citation Format

Share Document